NCT01548378已完成2 期
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 9
- 主要终点
- The difference in ulcer area between baseline and the D180.
研究概览
简要总结
The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia
详细描述
Management of CLI process consumes a significant amount of healthcare resources,and the new therapeutic approaches are required.
Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.
This study will use NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with NL003 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, between 30 and 80years of age
- •Diagnosis of critical limb ischemia(ASO、TAO、DAO)，Rutherford Class 4 or 5, including:
- •A resting ankle systolic pressure of ≤ 70 mmHg in the affected limb; or
- •A resting toe systolic pressure of ≤ 50 mmHg in the affected limb; or
- •For patients in which measurement of ankle systolic pressure is not feasible , TcPO2 ≤ 30mmHg; Only unilateral affected limb receive treatment。
- •Significant stenosis (≥ 75%) of one or more of the following arteries:
- •superficial femoral, popliteal as verified by angiography（DSA、CTA、MRA） within 12 months prior to enrollment
- •Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study
- •Be willing to maintain ulcer treatment
- •Be willing to infertility throughout the course of the study
- •If the subject is of child-bearing potential, she must have a negative urine pregnancy test result prior to study enrollment
- •Tumor screening result is no clinic meaning，including:
- •Signing the informed consent document prior to being subjected to any study related procedures
排除标准
- •Subjects who have undergone a successful revascularization procedure or sympathectomy within 12 weeks prior to study entry.
- •Acute advanced CLI
- •Subjects that will require an amputation in the target leg within 4 weeks, or significant stenosis (≥ 75%) of Aortoiliac
- •Subjects with evidence of active infection or deep ulceration exposing bone or tendon in the extremity planned for treatment
- •Heart Failure with a NYHA classification of III or IV
- •Stroke、myocardial infarction or unstable angina within last 3 months
- •Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg
- •Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination
- •Can not correctly describe the symptoms and feeling
- •Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices
- •Subjects currently receiving immunosuppressive medications chemotherapy, or radiation therapy
- •Positive HIV,active Hepatitis B(determined by HBsAb\ HBcAb\HBsAg) or C infection
- •Specific laboratory values at Screening including: Hemoglobin < 8.0 g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary
- •Elevated PSA unless prostate cancer has been excluded
- •Patients with a recent history (< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings
- •Subjects requiring > 100 mg daily of acetylsalicylic acid,COX-2 inhibitor drug(s) or high dose steroids (excepting inhaled steroids)
- •Subjects with any co- morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 12 months
- •History of drug or alcohol abuse / dependence in the past 12 months
- •Use of an investigational drug or treatment in past 3 months
结局指标
主要结局
The difference in ulcer area between baseline and the D180.
时间窗: Day180
Rutherford 5 only
The difference in pain level between baseline and the D180 as determined by VAS
时间窗: Day 180
次要结局
- Difference in percentage of pain level decreased by 50% determined by VAS from baseline to D180(Day0、14、28、60、90、180)
- Difference in percentage of ulcer area decreased by 50% from baseline to D180(Day0、14、28、60、90、180)
- Ulcer healing after gangrene treatment(Day180)
- Difference in QOL score (VascuQol) from baseline to D180(Day0、14、28、60、90、180)
- Situation of ulcer healing(Day180)
- Major amputation rate(Day180)
- Change in tissue oxygenation (TcPO2) from baseline to D180(Day0、14、28、60、90、180)
- Difference in ABI and TBI from baseline to D180(Day0、14、28、60、90、180)
- Percentage of ulcer complete healing(Day180)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)IschemiaUlcersPeripheral Vascular DiseaseArterial Occlusive DiseaseNCT04274049Beijing Northland Biotech. Co., Ltd.242
已完成
2 期
Safety and Efficacy Study Using Gene Therapy for Critical Limb IschemiaCritical Limb IschemiaNCT01064440Helixmith Co., Ltd.52
已完成
3 期
Phase 3 Gene Therapy for Painful Diabetic NeuropathyPainful Diabetic NeuropathyDiabetic Neuropathy, PainfulNCT02427464Helixmith Co., Ltd.507
已完成
2 期
ACP-01 in Patients With Critical Limb IschemiaCritical Limb IschemiaNCT02551679Hemostemix67
已完成
2 期
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy AdultsEscherichia InfectionNCT06692907National Institute of Allergy and Infectious Diseases (NIAID)72